GSK Provides Update on P-III (DREAMM-7) Trial of Blenrep for Treating R/R Multiple Myeloma
Shots:
- GSK announced positive interim results from the P-III (DREAMM-7) trial assessing Blenrep (2.5mg/kg, IV, Q3W) with bortezomib & dexamethasone (BorDex) vs daratumumab & BorDex in patients (n=494) with r/r multiple myeloma
- The study achieved the 2EP of OS with the combination significantly reducing the risk of death vs daratumumab plus BorDex. Full results will be shared with regulatory authorities for approval & will be highlighted at ASH 2024
- The DREAMM program also includes the ongoing P-III (DREAMM-8) study of Blenrep with pomalidomide/dexamethasone vs bortezomib with pomalidomide/dexamethasone. Another P-III trial for newly-diagnosed transplant-ineligible multiple myeloma patients will begin by YE’24
Ref: GSK | Image: GSK
Related News:- GSK’s Ojjaara (Momelotinib) Receives the Health Canada’s Approval to Treat Myelofibrosis in Adults with Moderate to Severe Anemia
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
